Research advances of PEGylation modification of albumin as drug carrier

ZHOU Qinqin; CHEN Jianming

doi:10.3969/j.issn.1006-0111.2014.04.001

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 32 Issue 4

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2014 > 32(4): 241-245,265

ZHOU Qinqin, CHEN Jianming. Research advances of PEGylation modification of albumin as drug carrier[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001

Citation:

ZHOU Qinqin, CHEN Jianming. Research advances of PEGylation modification of albumin as drug carrier[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(4): 241-245,265. doi: 10.3969/j.issn.1006-0111.2014.04.001

Research advances of PEGylation modification of albumin as drug carrier

doi: 10.3969/j.issn.1006-0111.2014.04.001

ZHOU Qinqin¹,
CHEN Jianming^2
,

1.
Department of Pharmaceutical Preparations, School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-08-11
Rev Recd Date: 2013-12-25

Abstract

Albumin is an ideal drug carrier, but its application was limited because of the shortcomings of short half-life and susceptible to enzymatic degradation in vivo.However, according to its structural features, albumin has a plurality of modification sites, which can be modified by PEG modifier to extend the cycle time and obstruct the action of the enzyme.Currently, the PEG-modified albumin is still in the research stage, and there have been many studies about PEG-modified albumin, such as the role of PEG modification, the effects on albumin and its preparations and the modification sites selection.The article reviewed the related studies about the PEGylation of albumin.
- albumin,
- PEGylation,
- half-life,
- pharmaceutical characterization,
- modification sites

References

[1]	Gong J, Huo M, Zhou J, et al. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles[J].Int J Pharm, 2009,376(1-2): 161-168.
[2]	Hasan K, Seyed AS, Amir M, et al. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology[J].AAPS Pharm Sci Tech, 2010, 11(3): 1206-1211.
[3]	Zhang SF, Cezary K, Michael RD, et al. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery[J].Biomaterials, 2010, 31(5): 952-963.
[4]	Marion GA, Mahler HC, Klaus L. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients[J].Int J Pharm, 2008, 363(1-2): 162-169.
[5]	Bitten P, Conan JF, Peter W, et al. Effects of PEG size on structure, function and stability of PEGylated BSA[J].Eur J Pharm Biopharm, 2011, 79(2): 399-405.
[6]	Zhao T, Cheng YN, Tan HN, et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice[J].Biolog Pharm Bull, 2012, 35(3): 280-288.
[7]	Zhao T, Yang Y, Zong AZ, et al. N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention[J].Biol Sci Trends, 2012, 6(2): 81-88.
[8]	Wu L, Martin CG, Stanley SD, et al. Preparation and characterisation of rose bengal-loaded surface-modified albumin nanoparticles[J].J Contr Rel, 2011, 71(1): 117-126.
[9]	Franco D, Silvia A, Paola B, et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics[J].J Contr Rel, 2001, 76(1-2): 107-117.
[10]	Pedro C, Amy GT, Ananda K. Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin[J].Resuscitation, 2008, 79(1): 139-146.
[11]	Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers[J].Biochim Biophys Acta, 2002, 1590(1-3): 131-139.
[12]	周莉, 罗贵民, 高蛛娟, 等. 聚乙二醇修饰牛血请白蛋白[J].吉林大学自然科学学报,1997, (4): 63-66.
[13]	Jesse VJ, Tatsiana L, Richard NZ, et al. Nanoparticle PEGylation for imaging and therapy[J].Nanomedicine, 2001, 6(4): 715-728.
[14]	Wu L, Martin CG, Etienne S, et al. Preparation and in vitro characterization of HSA-mPEG nanoparticles[J].Int J Pharm, 1999, 189(2): 161-170.
[15]	孙诚谊, 刘建刚, 钱志勇, 等. 聚乙二醇修饰与未修饰磁性5-氟尿嘧啶白蛋白微球体外性质的比较[J].消化肿瘤杂志, 2008, 1(2): 110-113.
[16]	Beatriz F, Bibiana N, Hernan DN, et al. Thermal features of the bovine serum albumin unfolding by polyethylene glycols[J].Int J Biol Macromol, 1999, 26(1): 23-33.
[17]	Gianfranco P, Francesco MV. State of the art in PEGylation: the great versatility achieved after forty years of research[J].J Contr Rel, 2012, 161(2): 461-472.
[18]	徐超. 聚乙二醇修饰人血清白蛋白及其纳米微球制备[D]. 合肥工业大学, 2007.
[19]	Liu W, Zhang ZQ, Liu CM, et al. Effect of molecular patch modification on the stability of dynamic high-pressure microfluidization treated trypsin[J].Innov Food Sci Emerg Tech, 2012, 16: 349-354.
[20]	Hou BB, Li SR, Li XH, et al. Design, preparation and in vitro bioactivity of mono-PEGylated recombinant hirudin[J].Chin J Chem Eng, 2007, 15(6): 775-780.
[21]	Veronese FM. Introduction and overview of peptide and protein PEGylation: a review of problems and solution[J].Biomaterials,2001, 22(5): 405-417.
[22]	Hu JL, Walter S. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH[J].Int J Pharm, 2011, 413(1-2): 140-146.
[23]	Stewart AJ, Blindauer CA, Berezenko S, et al. Role of Tyr84 in controlling the reactivity of Cys34 of human albumin[J].FEBS J, 2005, 272(2): 353-362.
[24]	Octaaf JMB, Jan FAL, Marcel JEF, et al. The molecular mechanism of the neutral-to-base transition of human serum albumin[J].J Biol Chem, 1989, 264(2): 953-959.
[25]	Kim SH, Jeong JH, Joe CO, et al. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate[J].J Contr Rel, 2005,103: 625-634.
[26]	袁飞, 王树斌, 彭志平, 等. 表皮生长因子受体靶向纳米载体荷载c-erbB2反义寡脱氧核苷酸对人乳腺癌SK-BR3细胞的摄取和滞留[J].中国组织工程研究与临床康复, 2009,13(16): 3084-3088.
[27]	Choi N, Kim SM, Hong KS, et al. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging[J].Biomaterials, 2011, 32: 7151-7158.
[28]	Parikh T, Bommana MM, Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain[J].Eur J Pharm Biopharm, 2010, 74: 442-450.
[29]	Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons[J].J Contr Rel, 2009, 137: 78-86.
[30]	Kreuter J, Hekmatara T, Dreis S, et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain[J].J Contr Rel, 2007, 118: 54-58.
[31]	Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin and transferrin-receptor-antibody modified nanoparticles enable drug delivery across the blood-brain barrier(BBB)[J]. Eur J Pharm Biopharm, 2009, 71: 251-256.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3099) PDF downloads(371) Cited by()

Proportional views

Research advances of PEGylation modification of albumin as drug carrier

1. Department of Pharmaceutical Preparations, School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-08-11

Rev Recd Date: 2013-12-25

Key words:

Abstract: Albumin is an ideal drug carrier, but its application was limited because of the shortcomings of short half-life and susceptible to enzymatic degradation in vivo.However, according to its structural features, albumin has a plurality of modification sites, which can be modified by PEG modifier to extend the cycle time and obstruct the action of the enzyme.Currently, the PEG-modified albumin is still in the research stage, and there have been many studies about PEG-modified albumin, such as the role of PEG modification, the effects on albumin and its preparations and the modification sites selection.The article reviewed the related studies about the PEGylation of albumin.

HTML

Reference (31)

[1]	Gong J, Huo M, Zhou J, et al. Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles[J].Int J Pharm, 2009,376(1-2): 161-168.
[2]	Hasan K, Seyed AS, Amir M, et al. Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology[J].AAPS Pharm Sci Tech, 2010, 11(3): 1206-1211.
[3]	Zhang SF, Cezary K, Michael RD, et al. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery[J].Biomaterials, 2010, 31(5): 952-963.
[4]	Marion GA, Mahler HC, Klaus L. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients[J].Int J Pharm, 2008, 363(1-2): 162-169.
[5]	Bitten P, Conan JF, Peter W, et al. Effects of PEG size on structure, function and stability of PEGylated BSA[J].Eur J Pharm Biopharm, 2011, 79(2): 399-405.
[6]	Zhao T, Cheng YN, Tan HN, et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice[J].Biolog Pharm Bull, 2012, 35(3): 280-288.
[7]	Zhao T, Yang Y, Zong AZ, et al. N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention[J].Biol Sci Trends, 2012, 6(2): 81-88.
[8]	Wu L, Martin CG, Stanley SD, et al. Preparation and characterisation of rose bengal-loaded surface-modified albumin nanoparticles[J].J Contr Rel, 2011, 71(1): 117-126.
[9]	Franco D, Silvia A, Paola B, et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics[J].J Contr Rel, 2001, 76(1-2): 107-117.
[10]	Pedro C, Amy GT, Ananda K. Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin[J].Resuscitation, 2008, 79(1): 139-146.
[11]	Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers[J].Biochim Biophys Acta, 2002, 1590(1-3): 131-139.
[12]	周莉, 罗贵民, 高蛛娟, 等. 聚乙二醇修饰牛血请白蛋白[J].吉林大学自然科学学报,1997, (4): 63-66.
[13]	Jesse VJ, Tatsiana L, Richard NZ, et al. Nanoparticle PEGylation for imaging and therapy[J].Nanomedicine, 2001, 6(4): 715-728.
[14]	Wu L, Martin CG, Etienne S, et al. Preparation and in vitro characterization of HSA-mPEG nanoparticles[J].Int J Pharm, 1999, 189(2): 161-170.
[15]	孙诚谊, 刘建刚, 钱志勇, 等. 聚乙二醇修饰与未修饰磁性5-氟尿嘧啶白蛋白微球体外性质的比较[J].消化肿瘤杂志, 2008, 1(2): 110-113.
[16]	Beatriz F, Bibiana N, Hernan DN, et al. Thermal features of the bovine serum albumin unfolding by polyethylene glycols[J].Int J Biol Macromol, 1999, 26(1): 23-33.
[17]	Gianfranco P, Francesco MV. State of the art in PEGylation: the great versatility achieved after forty years of research[J].J Contr Rel, 2012, 161(2): 461-472.
[18]	徐超. 聚乙二醇修饰人血清白蛋白及其纳米微球制备[D]. 合肥工业大学, 2007.
[19]	Liu W, Zhang ZQ, Liu CM, et al. Effect of molecular patch modification on the stability of dynamic high-pressure microfluidization treated trypsin[J].Innov Food Sci Emerg Tech, 2012, 16: 349-354.
[20]	Hou BB, Li SR, Li XH, et al. Design, preparation and in vitro bioactivity of mono-PEGylated recombinant hirudin[J].Chin J Chem Eng, 2007, 15(6): 775-780.
[21]	Veronese FM. Introduction and overview of peptide and protein PEGylation: a review of problems and solution[J].Biomaterials,2001, 22(5): 405-417.
[22]	Hu JL, Walter S. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH[J].Int J Pharm, 2011, 413(1-2): 140-146.
[23]	Stewart AJ, Blindauer CA, Berezenko S, et al. Role of Tyr84 in controlling the reactivity of Cys34 of human albumin[J].FEBS J, 2005, 272(2): 353-362.
[24]	Octaaf JMB, Jan FAL, Marcel JEF, et al. The molecular mechanism of the neutral-to-base transition of human serum albumin[J].J Biol Chem, 1989, 264(2): 953-959.
[25]	Kim SH, Jeong JH, Joe CO, et al. Folate receptor mediated intracellular protein delivery using PLL-PEG-FOL conjugate[J].J Contr Rel, 2005,103: 625-634.
[26]	袁飞, 王树斌, 彭志平, 等. 表皮生长因子受体靶向纳米载体荷载c-erbB2反义寡脱氧核苷酸对人乳腺癌SK-BR3细胞的摄取和滞留[J].中国组织工程研究与临床康复, 2009,13(16): 3084-3088.
[27]	Choi N, Kim SM, Hong KS, et al. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging[J].Biomaterials, 2011, 32: 7151-7158.
[28]	Parikh T, Bommana MM, Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain[J].Eur J Pharm Biopharm, 2010, 74: 442-450.
[29]	Zensi A, Begley D, Pontikis C, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons[J].J Contr Rel, 2009, 137: 78-86.
[30]	Kreuter J, Hekmatara T, Dreis S, et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain[J].J Contr Rel, 2007, 118: 54-58.
[31]	Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin and transferrin-receptor-antibody modified nanoparticles enable drug delivery across the blood-brain barrier(BBB)[J]. Eur J Pharm Biopharm, 2009, 71: 251-256.

Message Board

Research advances of PEGylation modification of albumin as drug carrier

doi: 10.3969/j.issn.1006-0111.2014.04.001

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views